Neurocrine Biosciences
NBIX
529 hedge funds and large institutions have $10.7B invested in Neurocrine Biosciences in 2022 Q4 according to their latest regulatory filings, with 108 funds opening new positions, 195 increasing their positions, 170 reducing their positions, and 39 closing their positions.
875% more call options, than puts
Call options by funds: $38M | Put options by funds: $3.89M
177% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 39
15% more repeat investments, than reductions
Existing positions increased: 195 | Existing positions reduced: 170
14% more funds holding
Funds holding: 466 → 529 (+63)
7% more capital invested
Capital invested by funds: $10B → $10.7B (+$704M)
5.94% less ownership
Funds ownership: 99.65% → 93.7% (-5.9%)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$177M |
| 2 |
BlackRock
New York
|
+$68M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$61.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$52M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$51.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$871M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$107M |
| 3 |
AC
Armistice Capital
New York
|
-$49.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$42M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$29.9M |
NBIX Hedge Fund Activity: Q4 2022 in Review
529 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2022, worth a combined $10.7B — up 7% from $10B a quarter earlier.
Buyers outnumbered sellers: 108 funds opened new NBIX positions and 39 closed out — a net gain of 69 holders — while 195 added to existing stakes and 170 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $177M. The largest seller was Janus Henderson Group, cutting an estimated $871M.
- 529 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2022, up from 466 in Q3 2022.
- Funds reported $10.7B of Neurocrine Biosciences stock for Q4 2022, up 7% quarter-over-quarter.
- 108 funds opened new Neurocrine Biosciences positions in Q4 2022 and 39 closed out, a net change of +69 holders.
- The largest Neurocrine Biosciences buyer in Q4 2022 was Morgan Stanley, an estimated $177M added.
- The largest Neurocrine Biosciences seller in Q4 2022 was Janus Henderson Group, an estimated $871M sold.
Based on aggregated 13F filings for Q4 2022.